Anebulo Financial Statements From 2010 to 2026

ANEB Stock

USD 1.13 0.12 11.88%

Anebulo Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Anebulo Pharmaceuticals' valuation are provided below:

Market Capitalization

46.4 M

Earnings Share

(0.22)

We have found ninety-seven available fundamental signals for Anebulo Pharmaceuticals, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Anebulo Pharmaceuticals prevailing market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road.

Check Anebulo Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Anebulo Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 311.4 K, Depreciation And Amortization of 220.8 K or Interest Expense of 461.3 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 4.56. Anebulo financial statements analysis is a perfect complement when working with Anebulo Pharmaceuticals Valuation or Volatility modules.

Build AI portfolio with Anebulo Stock

Check out the analysis of Anebulo Pharmaceuticals Correlation against competitors.

For information on how to trade Anebulo Stock refer to our How to Trade Anebulo Stock guide.

Anebulo Pharmaceuticals Balance Sheet

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Total Assets

9.1 M

10.9 M

6.8 M

Slightly volatile

Short and Long Term Debt Total

161 K

181.2 K

197.7 K

Slightly volatile

Other Current Liabilities

203.3 K

119.8 K

91.5 K

Slightly volatile

Total Current Liabilities

464.1 K

257.8 K

309.9 K

Slightly volatile

Total Stockholder Equity

8.7 M

10.5 M

6.5 M

Slightly volatile

Cash

8.5 M

10.5 M

6.5 M

Slightly volatile

Cash And Short Term Investments

8.5 M

10.5 M

6.5 M

Slightly volatile

Net Receivables

42.2 K

84.2 K

31 K

Slightly volatile

Common Stock Total Equity

19.4 K

26.8 K

16.6 K

Slightly volatile

Common Stock Shares Outstanding

28.4 M

38.9 M

25.6 M

Slightly volatile

Liabilities And Stockholders Equity

9.1 M

10.9 M

6.8 M

Slightly volatile

Capital Surpluse

1.2 K

1.4 K

1.5 K

Slightly volatile

Other Current Assets

223.5 K

235.3 K

250.3 K

Slightly volatile

Other Stockholder Equity

62.9 M

98.3 M

29.7 M

Slightly volatile

Total Liabilities

512.4 K

560.8 K

346.1 K

Slightly volatile

Net Invested Capital

9.5 M

13.4 M

4.4 M

Slightly volatile

Short and Long Term Debt

161 K

181.2 K

197.7 K

Slightly volatile

Total Current Assets

9 M

10.8 M

6.7 M

Slightly volatile

Capital Stock

28.2 K

47.2 K

19.8 K

Slightly volatile

Net Working Capital

9.9 M

13.2 M

6 M

Slightly volatile

Short Term Debt

161 K

181.2 K

197.7 K

Slightly volatile

Common Stock

27.7 K

47.2 K

19.7 K

Slightly volatile

Non Currrent Assets Other

299.3 K

164.8 K

503.5 K

Slightly volatile

Anebulo Pharmaceuticals Income Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Interest Income

311.4 K

296.6 K

80.9 K

Slightly volatile

Depreciation And Amortization

220.8 K

232.5 K

1.3 M

Very volatile

Selling General Administrative

3.9 M

5.7 M

1.9 M

Slightly volatile

Selling And Marketing Expenses

4.1 K

4.3 K

15.6 K

Slightly volatile

Other Operating Expenses

7.3 M

10.6 M

3.5 M

Slightly volatile

Research Development

3.5 M

4.9 M

1.7 M

Slightly volatile

Total Operating Expenses

7.3 M

10.6 M

3.5 M

Slightly volatile

Anebulo Pharmaceuticals Cash Flow Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Sale Purchase Of Stock

6.2 M

9.4 M

5.1 M

Slightly volatile

Other Non Cash Items

261.8 K

275.6 K

1.7 M

Pretty Stable

Change To Operating Activities

653.9 K

1.2 M

461.8 K

Slightly volatile

End Period Cash Flow

8.5 M

10.5 M

6.5 M

Slightly volatile

Change To Netincome

1.1 M

1 M

363.7 K

Slightly volatile

Stock Based Compensation

1.7 M

540.1 K

Slightly volatile

Begin Period Cash Flow

2.6 M

2.8 M

5.2 M

Slightly volatile

Dividends Paid

6.6 M

7.4 M

8.1 M

Slightly volatile

Depreciation

293.3 K

439.3 K

190.1 K

Slightly volatile

Financial Ratios

Trends

Current Value

Last Year

Historical Average

10 Year Trend

PTB Ratio

4.56

4.8

38.4194

Slightly volatile

Book Value Per Share

0.47

0.4

0.2665

Slightly volatile

Average Payables

364.3 K

218.8 K

415.8 K

Slightly volatile

Capex To Depreciation

0.0

Slightly volatile

PB Ratio

4.56

4.8

38.4194

Slightly volatile

Cash Per Share

0.46

0.4

0.2663

Slightly volatile

Income Quality

0.58

0.67

0.7883

Slightly volatile

Current Ratio

38.95

61.37

25.5625

Slightly volatile

Tangible Book Value Per Share

0.47

0.4

0.2665

Slightly volatile

Shareholders Equity Per Share

0.47

0.4

0.2665

Slightly volatile

Debt To Equity

0.0574

0.0646

0.0705

Slightly volatile

Graham Net Net

0.44

0.38

0.2527

Slightly volatile

Interest Debt Per Share

0.0107

0.0102

0.0077

Very volatile

Debt To Assets

0.0532

0.0598

0.0653

Slightly volatile

Price Book Value Ratio

4.56

4.8

38.4194

Slightly volatile

Ebt Per Ebit

1.01

1.06

1.4363

Very volatile

Company Equity Multiplier

0.85

0.94

1.0497

Slightly volatile

Total Debt To Capitalization

0.0536

0.0603

0.0658

Slightly volatile

Debt Equity Ratio

0.0574

0.0646

0.0705

Slightly volatile

Quick Ratio

38.95

61.37

25.5625

Slightly volatile

Cash Ratio

38.39

59.65

25.238

Slightly volatile

Price To Book Ratio

4.56

4.8

38.4194

Slightly volatile

Debt Ratio

0.0532

0.0598

0.0653

Slightly volatile

Price Fair Value

4.56

4.8

38.4194

Slightly volatile

Anebulo Pharmaceuticals Valuation Data

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Market Cap

53.2 M

56 M

119.8 M

Slightly volatile

Enterprise Value

40.5 M

42.6 M

113.2 M

Slightly volatile

Anebulo Fundamental Market Drivers

Anebulo Upcoming Events

	9th of February 2024 Upcoming Quarterly Report	View
	9th of May 2024 Next Financial Report	View
	31st of December 2023 Next Fiscal Quarter End	View
	18th of September 2024 Next Fiscal Year End	View
	30th of September 2023 Last Quarter Report	View
	30th of June 2023 Last Financial Announcement	View

About Anebulo Pharmaceuticals Financial Statements

Anebulo Pharmaceuticals stakeholders use historical fundamental indicators, such as Anebulo Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Anebulo Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Anebulo Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Anebulo Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Anebulo Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.

Last Reported

Projected for Next Year

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

JBL	Jabil Circuit
MRK	Merck Company
AMGN	Amgen Inc

When determining whether Anebulo Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Anebulo Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Anebulo Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Anebulo Pharmaceuticals Stock:

How To Invest In Anebulo

Details

Is Anebulo Stock a good investment?

Details

What is Anebulo Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Anebulo Pharmaceuticals Correlation against competitors.

For information on how to trade Anebulo Stock refer to our How to Trade Anebulo Stock guide.

You can also try the AI Portfolio Prophet module to use AI to generate optimal portfolios and find profitable investment opportunities.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anebulo Pharmaceuticals. If investors know Anebulo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anebulo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.22)

Return On Assets

(0.86)

Return On Equity

(1.45)

The market value of Anebulo Pharmaceuticals is measured differently than its book value, which is the value of Anebulo that is recorded on the company's balance sheet. Investors also form their own opinion of Anebulo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Anebulo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anebulo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Anebulo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Anebulo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anebulo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anebulo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Anebulo Financial Statements From 2010 to 2026

Anebulo Pharmaceuticals Balance Sheet

Anebulo Pharmaceuticals Income Statement

Anebulo Pharmaceuticals Cash Flow Statement

Financial Ratios

Anebulo Pharmaceuticals Valuation Data

Anebulo Fundamental Market Drivers

Anebulo Upcoming Events

About Anebulo Pharmaceuticals Financial Statements

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY